Overview

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

Status:
Completed
Trial end date:
2021-02-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept